

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	01/07/20

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Ippolito is a trustee of the Ippolito Trust
Date of change	07/07/2022
No. of securities held prior to change	
Vincent Peter Ippolito	12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023
Vincent Peter Ippolito	17,994,914 Unlisted Options exercisable at 0.0551 each, expiring 30 June 2022
Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
Class	Ordinary Shares Unlisted Options
Number acquired	5,286,493 Ordinary Shares
Number disposed	17,994,914 Unlisted Options

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.0551 per share
No. of securities held after the change Vincent Peter Ippolito Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust>	5,286,493 Ordinary Shares 12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023 3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Options utilising cashless exercise facility

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	01/07/2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	07/07/2022
No. of securities held prior to change	16,000,000 Ordinary Shares 4,863,490 Unlisted Options exercisable at 0.0551 each, expiring 30 June 2022
Class	Ordinary Shares Unlisted Options
Number acquired	321,551 Ordinary Shares
Number disposed	4,863,490 Unlisted Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.0551 per share
No. of securities held after change	16,321,551 Ordinary Shares

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Options utilising cashless exercise facility
---	---

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	22/02/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust (Dr Washer is a trustee and beneficiary of the trust)

Date of change	21/02/2022
No. of securities held prior to change Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust	4,863,490 Unlisted Options exercisable at 0.0551 each, expiring 30 June 2022
Class	Ordinary Shares Unlisted options
Number acquired	321,551 Ordinary Shares
Number disposed	4,863,490 Unlisted Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.0551 per share

+ See chapter 19 for defined terms.

No. of securities held after change Dr Stewart James Washer & Dr Patrizia Derna Washer as trustee for the Washer Family Trust	321,551 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Unlisted Options utilising cashless exercise facility

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.